Arthur T. Suckow, PhD

Board, Executive chair

Dr. Suckow is an innovative executive leader and scientist with 15 years of experience leading drug development programs across multiple therapeutic areas leveraging small molecules, biologics and oligonucleotides. Most recently, he founded DTx Pharma and served as its Chief Executive Officer until it was acquired for $1B by Novartis. In 6 years, he helped this San Diego-based RNA therapeutics company develop a pipeline of therapies for rare neurological and muscular diseases and raise more than $120M through grants and leading healthcare investors. He currently serves as a strategic advisor or board member to Transcera, Actio Biosciences, Palm Therapeutics, Sinopia Biosciences, CMT Research Foundation, and several investment groups. Prior to DTx, he served in roles of increasing responsibility at Johnson & Johnson, MedImmjune/AstraZeneca and Regulus Therapeutics. Dr. Suckow received his undergraduate degree in Biological Sciences from University of Delaware and his PhD in Biomedical Sciences/Pharmacology from University of California, San Diego.